Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $624,210.93 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

David Sponsel also recently made the following trade(s):

• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Price Performance

NASDAQ ATEC opened at $11.29 on Friday. The firm’s 50 day moving average is $9.63 and its 200-day moving average is $8.05. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a market capitalization of $1.60 billion, a PE ratio of -8.82 and a beta of 1.41. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $17.34.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Barclays raised their price target on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Needham & Company LLC lifted their price target on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Tuesday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.44.

Institutional Investors Weigh In On Alphatec

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in shares of Alphatec during the 3rd quarter worth about $69,000. Net Worth Advisory Group acquired a new position in Alphatec during the third quarter valued at approximately $76,000. Van ECK Associates Corp grew its stake in Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after purchasing an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC acquired a new position in shares of Alphatec during the 3rd quarter worth approximately $107,000. Finally, Atria Investments Inc raised its stake in shares of Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.